2022
Bayesian local exchangeability design for phase II basket trials
Liu Y, Kane M, Esserman D, Blaha O, Zelterman D, Wei W. Bayesian local exchangeability design for phase II basket trials. Statistics In Medicine 2022, 41: 4367-4384. PMID: 35777367, PMCID: PMC10279458, DOI: 10.1002/sim.9514.Peer-Reviewed Original Research
2021
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, Ralabate A, Johnson B, Levit NS, Anderson G, Zelterman D, Wei W, Mahajan A, Trifan O, Bosenberg M, Kaech SM, Perry CJ, Damsky W, Gettinger S, Sznol M, Hurwitz M, Kluger HM. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clinical Cancer Research 2021, 27: 4757-4767. PMID: 34140403, PMCID: PMC9236708, DOI: 10.1158/1078-0432.ccr-21-0903.Peer-Reviewed Original ResearchConceptsAnti-PD-1/PD-L1Non-small cell lung cancerCell lung cancerRenal cell carcinomaPD-L1Lung cancerDisease progressionCommon treatment-related adverse eventsPD-1/PD-L1 inhibitorsTreatment-related adverse eventsPhase 2 doseSubstantial clinical challengeUnconfirmed partial responseDose-limiting toxicityPD-L1 inhibitorsPhase I trialDose-escalation designPro-inflammatory cytokinesMultiple tumor typesAsymptomatic elevationStable diseaseIntolerable toxicityAdverse eventsMedian durationPartial responseImpact of structural ageism on greater violence against older persons: a cross-national study of 56 countries
Chang ES, Monin JK, Zelterman D, Levy BR. Impact of structural ageism on greater violence against older persons: a cross-national study of 56 countries. BMJ Open 2021, 11: e042580. PMID: 33986041, PMCID: PMC8126306, DOI: 10.1136/bmjopen-2020-042580.Peer-Reviewed Original ResearchConceptsGreater violenceMadrid International PlanTypes of violencePrevalence of violenceHuman rights protectionCross-national studyPolitical rightsTypes of prejudiceNational policyViolence dataWorld BankNational pollsViolenceUnited NationsSocial normsRights protectionOlder personsInternational PlanAgeismCountriesNegative attitudesStigma measuresPollsPolicyPrevalence rates
2013
Beta prime regression with application to risky behavior frequency screening
Tulupyev A, Suvorova A, Sousa J, Zelterman D. Beta prime regression with application to risky behavior frequency screening. Statistics In Medicine 2013, 32: 4044-4056. PMID: 23616229, PMCID: PMC3789864, DOI: 10.1002/sim.5820.Peer-Reviewed Original Research
2012
The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer
Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP. The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer. PLOS ONE 2012, 7: e37891. PMID: 22662244, PMCID: PMC3360659, DOI: 10.1371/journal.pone.0037891.Peer-Reviewed Original ResearchConceptsPrimary patientsOvarian cancer riskKRAS-variantOvarian cancer diagnosisOvarian cancerPrimary cancerFamily historyCancer diagnosisCancer riskTriple-negative breast cancerAdditional cancer diagnosesDouble primary breastTriple primary cancersPositive family historyAge of diagnosisNegative breast cancerDeleterious BRCA mutationsBreast primaryPathologic diagnosisBRCA mutationsPrimary breastBreast cancerHBOC familiesPatientsHereditary breast
2010
Metachronous Primary Melanoma and Lymphoma
McIntosh BC, Ariyan S, Esche G, Zelterman D, Narayan D. Metachronous Primary Melanoma and Lymphoma. Annals Of Plastic Surgery 2010, 64: 229-232. PMID: 20098111, DOI: 10.1097/sap.0b013e3181a13dbf.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaTumor RegistryYale-New Haven HospitalConnecticut Tumor RegistryEffect of treatmentStudy patientsCutaneous melanomaSurvival differencesPrimary melanomaLymphomaPatientsMelanomaViral inductionDiagnosisGenetic mutationsSurvivalRegistryLonger intervalsMalesGender comparisonsFurther researchImmunosuppressionMalignancyNeoplasmsHospital
2006
Postoperative Radiotherapy for Stage II or III Non–Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database
Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative Radiotherapy for Stage II or III Non–Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database. Journal Of Clinical Oncology 2006, 24: 2998-3006. PMID: 16769986, DOI: 10.1200/jco.2005.04.6110.Peer-Reviewed Original ResearchConceptsT3-4 tumour stageUse of PORTN2 nodal diseaseEnd Results (SEER) databasePostoperative radiotherapyCell lung cancerLymph nodesNodal diseaseResults databaseTumor stageLung cancerNode stageStage IIHigher American Joint CommitteeAdvanced node stageAmerican Joint CommitteePopulation-based cohortLarger tumor sizeMedian followPerioperative mortalityMale sexTumor sizeSubset analysisCancer stageInclusion criteria
2003
Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary.
Tangir J, Zelterman D, Ma W, Schwartz P. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstetrics And Gynecology 2003, 101: 251-7. PMID: 12576247, DOI: 10.1016/s0029-7844(02)02508-5.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBiopsy, NeedleChemotherapy, AdjuvantCohort StudiesCombined Modality TherapyFemaleFertilityFollow-Up StudiesGerminomaHumansInfertility, FemaleLogistic ModelsMiddle AgedMinimally Invasive Surgical ProceduresNeoplasm StagingOvarian NeoplasmsOvariectomyPregnancyProbabilityRetrospective StudiesRisk AssessmentSurvival RateTreatment OutcomeConceptsMalignant germ cell tumorsGerm cell tumorsFertility-preserving surgeryCell tumorsFollow-upReproductive functionInternational Federation of Gynecology and Obstetrics (FIGO) stage ITreated with other combinationsStage IIIStage IFIGO stage IFertility-preserving treatmentMedian follow-upLoss of follow-upActinomycin DCase series analysisReproductive function of womenFollow-up informationConservative surgeryNo chemotherapyCongenital anomaliesFunction of womenChemotherapyTumorCisplatin
2002
Statistical Inference for Familial Disease Clusters
Yu C, Zelterman D. Statistical Inference for Familial Disease Clusters. Biometrics 2002, 58: 481-491. PMID: 12229982, DOI: 10.1111/j.0006-341x.2002.00481.x.Peer-Reviewed Original Research
2001
The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
Peng X, Won J, Rutherford T, Fujii T, Zelterman D, Pizzorno G, Sapi E, Leavitt J, Kacinski B, Crystal R, Schwartz P, Deisseroth A. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Research 2001, 61: 4405-13. PMID: 11389068.Peer-Reviewed Original ResearchMeSH KeywordsAdenoviridaeAnimalsCytomegalovirusCytosine DeaminaseFemaleFlucytosineFluorouracilGene ExpressionGenetic TherapyGenetic VectorsHumansInhibitory Concentration 50Lac OperonMembrane GlycoproteinsMiceMice, NudeMicrofilament ProteinsNucleoside DeaminasesOvarian NeoplasmsPhosphoproteinsPromoter Regions, GeneticTumor Cells, CulturedUrinary Bladder NeoplasmsXenograft Model Antitumor AssaysConceptsL-plastin promoterBladder cancer cell linesNormal ovarian cellsCancer cell linesOvarian cancer cellsTumor nodulesAdenoviral vectorCell linesNormal peritoneal mesothelial cellsOvarian cellsCD vectorSKOV-3 ovarian cancer cell lineFibroblast cell lineReplication-incompetent adenoviral vectorCancer cellsOvarian cancer cell linesNormal peritoneal cellsPeritoneal mesothelial cellsMouse xenograft modelCytosine deaminase geneSurgical specimensOvarian cancerTumor-specific gene expressionPeritoneal cellsOVCAR-5
2000
Patterns of response to acute naloxone infusion in Tourette's syndrome
van Wattum P, Chappell P, Zelterman D, Scahill L, Leckman J. Patterns of response to acute naloxone infusion in Tourette's syndrome. Movement Disorders 2000, 15: 1252-1254. PMID: 11104215, DOI: 10.1002/1531-8257(200011)15:6<1252::aid-mds1030>3.0.co;2-i.Peer-Reviewed Original ResearchConceptsTourette syndromeTic behaviorsOpioid antagonist naloxoneDose-related effectsDose-response effectExpression of TSRandomized dosesAntagonist naloxoneNaloxone infusionOpioid receptorsLow doseHigh doseEarlier pilot studyPattern of responseSyndromeNaloxoneTS subjectsPilot studySignificant decreaseSignificant increaseDoseDifferent dosagesOpposite effectSubjectsVideotaped recordings
1999
Follow‐up recommendations for patients with American Joint Committee on Cancer Stages I–III malignant melanoma
Poo‐Hwu W, Ariyan S, Lamb L, Papac R, Zelterman D, Hu G, Brown J, Fischer D, Bolognia J, Buzaid A. Follow‐up recommendations for patients with American Joint Committee on Cancer Stages I–III malignant melanoma. Cancer 1999, 86: 2252-2258. PMID: 10590365, DOI: 10.1002/(sici)1097-0142(19991201)86:11<2252::aid-cncr12>3.0.co;2-q.Peer-Reviewed Original ResearchConceptsCancer stage IAmerican Joint CommitteePatient education programStage IYale Melanoma UnitSurveillance scheduleSymptomatic recurrenceMelanoma UnitSurveillance examinationsJoint CommitteeOverall survival rateStage of diseaseDetection of recurrenceAsymptomatic recurrenceAsymptomatic patientsDistant recurrenceLocoregional recurrenceHazard ratioDisease recurrenceInitial visitMore recurrencesMost recurrencesLate recurrenceMelanoma patientsRecurrence groupBinary Regression for Risks in Excess of Subject-Specific Thresholds
Zhang H, Zelterman D. Binary Regression for Risks in Excess of Subject-Specific Thresholds. Biometrics 1999, 55: 1247-1251. PMID: 11315077, DOI: 10.1111/j.0006-341x.1999.01247.x.Peer-Reviewed Original ResearchDownregulation of p27KIP1 and Ki67/Mib1 Labeling Index Support the Classification of Thyroid Carcinoma Into Prognostically Relevant Categories
Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S, Carcangiu M. Downregulation of p27KIP1 and Ki67/Mib1 Labeling Index Support the Classification of Thyroid Carcinoma Into Prognostically Relevant Categories. The American Journal Of Surgical Pathology 1999, 23: 678-685. PMID: 10366150, DOI: 10.1097/00000478-199906000-00007.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, FollicularAdultAgedCarcinoma, PapillaryCell Cycle ProteinsCyclin-Dependent Kinase Inhibitor p27Cyclin-Dependent KinasesDisease-Free SurvivalDown-RegulationFemaleHumansImmunoenzyme TechniquesKi-67 AntigenMaleMicrotubule-Associated ProteinsMiddle AgedPrognosisThyroid NeoplasmsTumor Suppressor ProteinsConceptsKi67/MIB1 labeling indexLow p27Kip1 expressionMIB1 labeling indexThyroid carcinomaFollicular carcinomaP27Kip1 expressionPathologic featuresPrognostic groupsTumor differentiationLabeling indexFavorable pathologic featuresKi67/MIB1Unfavorable pathologic featuresAdverse prognostic factorLarger tumor sizeFollicular cell originDownregulation of p27Kip1Valuable prognostic indicatorCellular proliferationCellular proliferation patternsCyclin-dependent kinase inhibitor p27Kip1High proliferative rateLow p27Kip1Prognostic factorsTumor sizeAssessment of Cardiac and Pulmonary Function in Adult Patients with Hodgkin's Disease Treated with ABVD or MOPP/ABVD Plus Adjuvant Low-Dose Mediastinal Irradiation
Salloum E, Tanoue L, Wackers F, Zelterman D, Hu G, Cooper D. Assessment of Cardiac and Pulmonary Function in Adult Patients with Hodgkin's Disease Treated with ABVD or MOPP/ABVD Plus Adjuvant Low-Dose Mediastinal Irradiation. Cancer Investigation 1999, 17: 171-180. PMID: 10099655, DOI: 10.3109/07357909909021418.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyDacarbazineDose-Response Relationship, RadiationDoxorubicinEvaluation Studies as TopicFemaleFollow-Up StudiesHeartHodgkin DiseaseHumansLungMaleMechlorethamineMiddle AgedPhysical ExertionPrednisoneProcarbazineRadiotherapy, AdjuvantRemission InductionRespiratory Function TestsVinblastineVincristineConceptsLeft ventricular ejection fractionMOPP/ABVDHodgkin's diseaseAdult patientsPulmonary functionInvolved-field radiation therapyFEV1/FVC ratioIU/m2Pulmonary function testsVentricular ejection fractionVital capacity valuesTotal lung capacityMediastinal irradiationPulmonary symptomsDiastolic functionModality therapyEjection fractionCardiopulmonary functionFunction testsFVC ratioStudy abnormalitiesCigarette smokersCardiac toxicityLung capacitySuch therapy
1998
Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation
Salloum E, Jillella A, Nadkarni R, Seropian S, Hu G, D'Andrea E, Zelterman D, Cooper D. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation. Cancer 1998, 82: 1506-1512. PMID: 9554528, DOI: 10.1002/(sici)1097-0142(19980415)82:8<1506::aid-cncr12>3.0.co;2-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarmustineCombined Modality TherapyCytarabineFemaleHeartHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansLungLymphoma, Non-HodgkinMaleMelphalanMiddle AgedNeutropeniaNeutrophilsPodophyllotoxinRespiratory Function TestsRetrospective StudiesVentricular Function, LeftConceptsHigh-dose chemotherapyPulmonary function testsPeripheral blood progenitor cell transplantationBlood progenitor cell transplantationProgenitor cell transplantationPBPC transplantationDose chemotherapyVital capacityCell transplantationAutologous peripheral blood progenitor cell transplantationAbnormal pulmonary function testsVentricular ejection fraction valuesHigh-dose therapyTotal lung capacityTime of reevaluationEjection fraction valuesEquilibrium radionuclide angiographyMediastinal irradiationAdditional therapyComplete remissionDose therapyPulmonary symptomsExpiratory volumePulmonary functionPFT valuesManaging Attribute–Value Clinical Trials Data Using the ACT/DB Client–Server Database System
Nadkarni P, Brandt C, Frawley S, Sayward F, Einbinder R, Zelterman D, Schacter L, Miller P. Managing Attribute–Value Clinical Trials Data Using the ACT/DB Client–Server Database System. Journal Of The American Medical Informatics Association 1998, 5: 139-151. PMID: 9524347, PMCID: PMC61285, DOI: 10.1136/jamia.1998.0050139.Peer-Reviewed Original ResearchConceptsClient-server database systemsReuse of parametersData entryOracle serverDatabase applicationsDatabase systemsObject dataUNIX platformsDictionary searchData typesInitial deploymentLogical groupingPurposes of displaySuch dataStandard reportPilot useServerIndexingAnalysis programMachineDeploymentPlatformReuseClients
1997
Log-linear modeling with the negative multinomial distribution.
Waller L, Zelterman D. Log-linear modeling with the negative multinomial distribution. Biometrics 1997, 53: 971-82. PMID: 9290226, DOI: 10.2307/2533557.Peer-Reviewed Original ResearchA 40-year analysis of 265 gastric carcinoids.
Modlin I, Sandor A, Tang L, Kidd M, Zelterman D. A 40-year analysis of 265 gastric carcinoids. The American Journal Of Gastroenterology 1997, 92: 633-8. PMID: 9128313.Peer-Reviewed Original ResearchConceptsGastric carcinoid tumorsGastric carcinoidsCarcinoid tumorsSurvival rateThird National Cancer SurveyAge-adjusted incidence ratesEnd Results (SEER) databaseNational Cancer SurveyAggressive biological behaviorNational Cancer InstituteEnd Results GroupDistant metastasisGastric malignancyCancer SurveyResults databaseFemale ratioMalignant neoplasmsIncidence rateBenign neoplasmsCarcinoidsCancer InstituteLocalized lesionsCarcinoid casesBiological behaviorWhite femalesGallium scans in the management of patients with Hodgkin's disease: a study of 101 patients.
Salloum E, Brandt D, Caride V, Cornelius E, Zelterman D, Schubert W, Mannino T, Cooper D. Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. Journal Of Clinical Oncology 1997, 15: 518-27. PMID: 9053473, DOI: 10.1200/jco.1997.15.2.518.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantChildFemaleGallium RadioisotopesHodgkin DiseaseHumansMaleMiddle AgedNeoplasm StagingPredictive Value of TestsRadiotherapy, AdjuvantTomography, Emission-Computed, Single-PhotonTreatment OutcomeConceptsNegative 67Ga scanPositive 67Ga scanTime of diagnosisManagement of patientsHodgkin's diseaseStage IIIStage IPredictive valueGallium scanGross residual diseaseEnd of therapyNegative predictive valueLow predictive valueModality therapyProgressive diseaseResidual diseasePositive scansRadiation therapyPatientsTherapyDiseaseScansTreatmentDiagnosisChemotherapy